505 related articles for article (PubMed ID: 24401224)
1. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.
Tardy C; Goffinet M; Boubekeur N; Ackermann R; Sy G; Bluteau A; Cholez G; Keyserling C; Lalwani N; Paolini JF; Dasseux JL; Barbaras R; Baron R
Atherosclerosis; 2014 Jan; 232(1):110-8. PubMed ID: 24401224
[TBL] [Abstract][Full Text] [Related]
2. HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE-/- Mice: Evidence of ABCA1 Down-Regulation.
Tardy C; Goffinet M; Boubekeur N; Cholez G; Ackermann R; Sy G; Keyserling C; Lalwani N; Paolini JF; Dasseux JL; Barbaras R; Baron R
PLoS One; 2015; 10(9):e0137584. PubMed ID: 26335690
[TBL] [Abstract][Full Text] [Related]
3. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
[TBL] [Abstract][Full Text] [Related]
4. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice.
Hasan ST; Zingg JM; Kwan P; Noble T; Smith D; Meydani M
Atherosclerosis; 2014 Jan; 232(1):40-51. PubMed ID: 24401215
[TBL] [Abstract][Full Text] [Related]
5. Reversal of atherosclerosis with apolipoprotein A1: back to basics.
Smits LP; Kootte RS; Stroes ES
Atherosclerosis; 2014 Jan; 232(1):217-9. PubMed ID: 24401241
[No Abstract] [Full Text] [Related]
6. Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings.
Keyserling CH; Barbaras R; Benghozi R; Dasseux JL
Clin Drug Investig; 2017 May; 37(5):483-491. PubMed ID: 28213743
[TBL] [Abstract][Full Text] [Related]
7. The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study.
Hovingh GK; Smits LP; Stefanutti C; Soran H; Kwok S; de Graaf J; Gaudet D; Keyserling CH; Klepp H; Frick J; Paolini JF; Dasseux JL; Kastelein JJ; Stroes ES
Am Heart J; 2015 May; 169(5):736-742.e1. PubMed ID: 25965722
[TBL] [Abstract][Full Text] [Related]
8. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
[TBL] [Abstract][Full Text] [Related]
9. HDL mimetic CER-001 targets atherosclerotic plaques in patients.
Zheng KH; van der Valk FM; Smits LP; Sandberg M; Dasseux JL; Baron R; Barbaras R; Keyserling C; Coolen BF; Nederveen AJ; Verberne HJ; Nell TE; Vugts DJ; Duivenvoorden R; Fayad ZA; Mulder WJM; van Dongen GAMS; Stroes ESG
Atherosclerosis; 2016 Aug; 251():381-388. PubMed ID: 27263077
[TBL] [Abstract][Full Text] [Related]
10. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia.
Belalcazar LM; Merched A; Carr B; Oka K; Chen KH; Pastore L; Beaudet A; Chan L
Circulation; 2003 Jun; 107(21):2726-32. PubMed ID: 12742997
[TBL] [Abstract][Full Text] [Related]
11. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.
Moore RE; Navab M; Millar JS; Zimetti F; Hama S; Rothblat GH; Rader DJ
Circ Res; 2005 Oct; 97(8):763-71. PubMed ID: 16151025
[TBL] [Abstract][Full Text] [Related]
12. LDL Receptor Regulates the Reverse Transport of Macrophage-Derived Unesterified Cholesterol via Concerted Action of the HDL-LDL Axis: Insight From Mouse Models.
Cedó L; Metso J; Santos D; García-León A; Plana N; Sabate-Soler S; Rotllan N; Rivas-Urbina A; Méndez-Lara KA; Tondo M; Girona J; Julve J; Pallarès V; Benitez-Amaro A; Llorente-Cortes V; Pérez A; Gómez-Coronado D; Ruotsalainen AK; Levonen AL; Sanchez-Quesada JL; Masana L; Kovanen PT; Jauhiainen M; Lee-Rueckert M; Blanco-Vaca F; Escolà-Gil JC
Circ Res; 2020 Aug; 127(6):778-792. PubMed ID: 32495699
[TBL] [Abstract][Full Text] [Related]
13. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type).
Ibanez B; Giannarelli C; Cimmino G; Santos-Gallego CG; Alique M; Pinero A; Vilahur G; Fuster V; Badimon L; Badimon JJ
Atherosclerosis; 2012 Jan; 220(1):72-7. PubMed ID: 22030095
[TBL] [Abstract][Full Text] [Related]
14. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice.
Tiniakou I; Kanaki Z; Georgopoulos S; Chroni A; Van Eck M; Fotakis P; Zannis VI; Kardassis D
Atherosclerosis; 2015 Nov; 243(1):77-85. PubMed ID: 26363436
[TBL] [Abstract][Full Text] [Related]
15. A selective peroxisome proliferator-activated receptor δ agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice.
Naya N; Fukao K; Nakamura A; Hamada T; Sugimoto M; Kojima M; Yoshimura N; Uwabe K; Imagawa K; Nomura K; Hara S; Nakano T; Iwasaki T; Shinosaki T; Hanasaki K
Metabolism; 2016 Jan; 65(1):16-25. PubMed ID: 26683793
[TBL] [Abstract][Full Text] [Related]
16. Deletion of amino acids Glu146-->Arg160 in human apolipoprotein A-I (ApoA-ISeattle) alters lecithin:cholesterol acyltransferase activity and recruitment of cell phospholipid.
Lindholm EM; Bielicki JK; Curtiss LK; Rubin EM; Forte TM
Biochemistry; 1998 Apr; 37(14):4863-8. PubMed ID: 9538003
[TBL] [Abstract][Full Text] [Related]
17. Methionine-induced hyperhomocysteinemia impairs the antioxidant ability of high-density lipoproteins without reducing in vivo macrophage-specific reverse cholesterol transport.
Julve J; Escolà-Gil JC; Rodríguez-Millán E; Martín-Campos JM; Jauhiainen M; Quesada H; Rentería-Obregón IM; Osada J; Sánchez-Quesada JL; Blanco-Vaca F
Mol Nutr Food Res; 2013 Oct; 57(10):1814-24. PubMed ID: 23754667
[TBL] [Abstract][Full Text] [Related]
18. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
19. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.
Amar MJ; D'Souza W; Turner S; Demosky S; Sviridov D; Stonik J; Luchoomun J; Voogt J; Hellerstein M; Sviridov D; Remaley AT
J Pharmacol Exp Ther; 2010 Aug; 334(2):634-41. PubMed ID: 20484557
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo.
Rotllan N; Ribas V; Calpe-Berdiel L; Martín-Campos JM; Blanco-Vaca F; Escolà-Gil JC
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):e128-32. PubMed ID: 15994442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
